Clinical trials: Margin, Tumor-Free
Endometrial Cancer
Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Endometrial Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00005583
- Testing
- cisplatin, doxorubicin hydrochloride, epirubicin hydrochloride
- Where
- 23 sites in Belgium, France and 9 more
- Volunteers
- 400 people
- Sponsor
- Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma
Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer
This randomized phase III trial studies carboplatin and paclitaxel to see how well they work with or without cisplatin and radiation therapy in treating patients with stage I-IVA endometrial cancer.
- Conditions
- Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Stage IA Uterine Corpus Cancer AJCC v7, Stage IB Uterine Corpus Cancer AJCC v7
- Trial name
- NCT00942357
- Testing
- Carboplatin, Cisplatin, Internal Radiation Therapy
- Where
- 670 sites in United States, Canada and 1 more
- Volunteers
- 813 people
- Sponsor
- Gynecologic Oncology Group
Endometrial Cancer
S9720 Combination Chemotherapy in Treating Patients With Metastatic, Recurrent, or Refractory Endometrial Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003127
- Testing
- amifostine trihydrate, carboplatin, paclitaxel
- Where
- 94 sites in United States
- Volunteers
- 57 people
- Sponsor
- SWOG Cancer Research Network
Hypercholesterolemia, Atherosclerotic Cardiovascular Disease
Assessment of the Long-Term Safety and Efficacy of Bempedoic Acid (CLEAR Harmony OLE)
The purpose of this study is to see if bempedoic acid (ETC-1002) is safe and well-tolerated in patients with high cardiovascular risk and elevated LDL cholesterol that is not adequately controlled by their current therapy.
- Trial name
- NCT03067441
- Testing
- bempedoic acid
- Where
- 3 sites in United States
- Volunteers
- 1,462 people
- Sponsor
- Esperion Therapeutics, Inc.
Cardiovascular Disease
Cardiovascular Longitudinal Evaluation & Assessment of Risk (CLEAR) Study
The burden of cardiovascular disease (CVD) is considerable, despite many advances in diagnosis, clinical management and drug therapy.
- Trial name
- CLEAR (NCT00495456)
- Where
- 4 sites in Australia
- Volunteers
- 665 people, healthy volunteers welcome
- Sponsor
- Monash University
Clear Cell Renal Cell Carcinoma, Solid Tumors
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
The purpose of this study is to evaluate the safety and tolerability of: casdatifan when taken alone in participants with advanced solid tumor malignancies and clear cell renal cell carcinoma (ccRCC) during the dose escalation…
- Trial name
- ARC-20 (NCT05536141)
- Testing
- casdatifan, Cabozantinib, Zimberelimab
- Where
- 25 sites in United States, Australia and 2 more
- Volunteers
- 362 people
- Sponsor
- Arcus Biosciences, Inc.
Coronary Artery Disease
A Single Arm Trial With Resolute Onyx in ONE-Month DAPT for High-Bleeding Risk Patients Who Are Considered One-Month Clear (Onyx ONE Clear)
The purpose of this trial is to evaluate the clinical safety and effectiveness of the Resolute Onyx stent in subjects deemed at high risk for bleeding and/or medically unsuitable for more than 1 month DAPT treatment receiving…
- Trial name
- Onyx ONE Clear (NCT03647475)
- Testing
- Device: Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent System Treatment Followed by one-month DAPT
- Where
- 4 sites in United States
- Volunteers
- 752 people
- Sponsor
- Medtronic Vascular
Metastatic Clear Cell Renal Cell Carcinoma
Phase II Study of Lutetium-177 Labeled Girentuximab in Patients With Advanced Renal Cancer
To determine the efficacy of multiple doses Lutetium-177-DOTA-girentuximab in patients with advanced clear cell renal cell carcinoma using RECIST criteria.
- Trial name
- NCT02002312
- Testing
- Lu-177-DOTA-girentuximab
- Where
- Netherlands
- Volunteers
- 14 people
- Sponsor
- Radboud University Medical Center
Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Cancer
Tremelimumab With or Without Cryoablation in Treating Patients With Metastatic Kidney Cancer
This randomized pilot clinical trial studies the side effects of tremelimumab with or without tissue cryoablation in treating patients with kidney cancer that has spread to other places in the body.
- Conditions
- Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Cancer, Stage IV Renal Cell Cancer AJCC v7
- Trial name
- NCT02626130
- Testing
- Cryosurgery, Laboratory Biomarker Analysis, Therapeutic Conventional Surgery
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Clear Cell Renal Carcinoma (Ccrcc), Papillary Renal Cell Carcinoma (Prcc)
Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)
Background: Kidney cancer is the 12th leading cause of cancer-related death in the United States. Some kidney tumors do not respond well to current treatments. Better treatments are needed.
- Trial name
- NCT05665361
- Testing
- Sasanlimab, Palbocicilib
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer
Witness Project Lung
The long-term objective is to improve lung cancer screening uptake among screening-eligible Black adults and thereby reduce the population burden of late-stage diagnosis and mortality.
- Trial name
- NCT07792824
- Testing
- Witness Project Lung, General Educational Program
- Where
- United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Hackensack Meridian Health
Microplastic Exposure
Microplastic Exposure From Clear Aligner Wear (MPE)
An observational longitudinal study measuring microplastic exposure and physiologic uptake in orthodontic patients receiving clear aligner treatment.
- Trial name
- MPE (NCT06934603)
- Testing
- Clear Aligner Treatment
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- University of North Carolina, Chapel Hill
Urinary Catheter, Urinary Tract Infections
Sharklet Catheter Study
The aim of this study is to determine if the Sharklet catheter, with its unique coating, reduces infections in participants, when compared to a standard catheter.
- Trial name
- NCT02669342
- Testing
- Radiance™ Clear Sharklet® Silicone Foley Catheter, Silicone Foley Catheter
- Where
- Canada
- Volunteers
- 32 people
- Sponsor
- University of British Columbia
Non-Clear Cell Renal Cell Carcinoma
Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma
This is a multicenter, randomized (2:1), open-label, controlled Phase 3 trial of XL092 in combination with nivolumab versus sunitinib in subjects with unresectable, locally advanced or metastatic nccRCC who have not received…
- Trial name
- STELLAR-304 (NCT05678673)
- Testing
- XL092, Nivolumab, Sunitinib Malate
- Where
- 163 sites in United States, Argentina and 23 more
- Volunteers
- 317 people
- Sponsor
- Exelixis
Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma
68Ga- and 18F-CAIX PET Imaging Study
This exploratory clinical imaging study will evaluate the safety, tolerability, biodistribution, lesion detection, and tumor uptake characteristics of 68Ga- and 18F-labeled carbonic anhydrase IX (CAIX)-targeted positron emission…
- Conditions
- Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Renal Tumor
- Trial name
- CAIX-PET (NCT07875946)
- Testing
- 68Ga-CAIX PET/CT, 18F-CAIX
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Peking University First Hospital
Pediatric Solid Tumor, Germ Cell Tumor
EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
This is a phase I, open-label, non-randomized study that will enroll pediatric and young adult research participants with relapsed or refractory non-CNS solid tumors to evaluate the safety, feasibility, and efficacy of…
- Conditions
- Pediatric Solid Tumor, Germ Cell Tumor, Retinoblastoma, Hepatoblastoma
- Trial name
- NCT03618381
- Testing
- second generation 4-1BBζ EGFR806-EGFRt, second generation 4-1BBζ EGFR806-EGFRt and a second generation 4 1BBζ CD19-Her2tG
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Seattle Children's Hospital
Bladder Urothelial Carcinoma, Clear Cell Renal Cell Carcinoma
Daratumumab in Treating Patients with Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer
Objectives: Primary: Safety and tolerability of therapy with daratumumab in a cohort of patients with metastatic renal cell carcinoma and a cohort of patients with muscle invasive bladder cancer. Secondary: 1A.
- Conditions
- Bladder Urothelial Carcinoma, Clear Cell Renal Cell Carcinoma, Malignant Urinary System Neoplasm, Metastatic Kidney Carcinoma
- Trial name
- NCT03473730
- Testing
- Biopsy, Daratumumab, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- M.D. Anderson Cancer Center
Fallopian Tube Cancer, Ovarian Cancer
Laparoscopic Staging in Patients With Ovarian, Fallopian Tube, or Other Primary Abdominal Cancers
RATIONALE: Laparoscopic staging may help doctors plan more effective treatment for ovarian, primary fallopian tube, and primary abdominal cancers.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00002538
- Testing
- laparoscopic surgery
- Where
- 11 sites in United States
- Sponsor
- Gynecologic Oncology Group
Oligometastatic Clear Cell Renal Cell Carcinoma
SABR Combined With Axitinib and Toripalimab for Oligometastatic Renal Cell Carcinoma
This is a phase II clinical trial testing whether a combination of stereotactic ablative radiotherapy (SABR), axitinib, and toripalimab is effective and safe for treating oligometastatic clear cell renal cell carcinoma (a type of…
- Trial name
- NCT07744932
- Testing
- axitinib plus toripalimab, SABR
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Hebei Medical University Fourth Hospital
Nausea/Vomiting
Trial of Low Residue Diet Versus Clear Liquids Following Elective Colorectal Surgery
Prospective randomized controlled trial investigating commencement of low residue diet versus clear liquids on postoperative zero following elective colorectal surgery, with regards to patient tolerability, incidence of nausea…
- Trial name
- NCT03260426
- Testing
- Clear Liquids, Regular Solid, Abstats
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Cedars-Sinai Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.